Tag Archives: peripheral vascular disease

FOURIER: Evolocumab Found Beneficial for Patients with Peripheral Vascular Disease of Prior MI

FOURIER: Evolocumab Found Beneficial for Patients with Peripheral Vascular Disease of Prior MI

Patients with peripheral vascular disease or prior acute myocardial infarction (especially within the first two years after the event) could find a particular benefit the PCSK9 receptor inhibitor evolocumab.   Given its high cost, the drug is not yet cost/effective and when prescribed, most patients were no table to complete the treatment. Read also: “Missed Opportunities with

Resultados a 2 años del balón farmacológico Lutonix sobre la femoral superficial

2 Year Outcomes of Lutonix Drug Coated Balloon in Superficial Femoral Arteries

  There are plenty of clinical studies assessing the use of angioplasty for en la peripheral artery disease with restenosis rates as high as 40% and 60% at 6 and 12 months. Drug coated balloons have significantly raised primary patency, but they have mostly been tested in short lesions with mild calcification and no total occlusions.   This

Trombosis y riesgo de sangrado

Risk of Thrombosis and Bleeding with Peripheral Artery Disease and Concomitants

Peripheral artery disease (PAD) is no longer a systemic manifestation of atherosclerosis. In fact, 2 in 3 people with PAD have concomitant heart disease, and 1 in 3 people has concomitant PAD.   To understand the real dimension of this problem, we should know that PAD patients have 60% more risk of acute myocardial infarction

Isquemia crítica de miembros inferiores: las re-hospitalizaciones frecuentes muestran la magnitud del problema

Critical ischemia in the lower limbs: Frequent Readmissions show the magnitude of this problem

Readmissions at 6 months in patients with critical ischemia in the lower limbs occur in about 50% of all cases and most of them are unplanned.   This truly alarming number is cause for further concern when taking into account that only part of these readmissions are related to vascular problems. Many are caused by comorbidities

ticagrelor vs clopidogrel en enfermedad vascular periferica

Ticagrelor Versus Clopidogrel in Symptomatic Peripheral Vascular Disease

Peripheral vascular disease is considered as a manifestation of systemic atherosclerosis associated with adverse events, both cardiovascular and related to the lower limbs.   Previous studies showed that clopidogrel monotherapy is associated with lower risk of events when compared to low doses of aspirin. Such is the rationale behind this article comparing clopidogrel and ticagrelor

plataformas bioabsorvibles BVS

BVS: Safe and Effective in the Infrapatellar Area

Courtesy of Dr. Carlos Fava. Drug-eluting stents (DES) have shown mid-term benefit in lesions below the knee (BTK) by reducing the rate of acute occlusion and restenosis in type A and B lesions. However, failure to recover the self-regulatory functions of the local vessel could hinder future revascularization. Drug-eluting bioresorbable scaffolds (BVS) could be a solution to this problem.

endoprotesis fenestradas aneurismas toracoabdominales

TAAA: Better Outcomes with Renal Fenestration

Courtesy of Dr. Carlos Fava.   Thoraco-abdominal aneurysms (TAAA) are a real challenge for surgeons. So far, endovascular repair have rendered good results in these aneurysms, but branch occlusion continues to be their Achilles’ heel”.   449 patients were analyzed, 235 (52%) were treated with branched devices (BEVAR) and 214 (48%) with fenestrated devices (FEVAR).

Drug-Coated Balloons in Complex Superficial Femoral Artery Lesions

Original Title: Drug-Coated Balloons for Complex Femoropopliteal Lesions2-Year Results of a Real-World Registry. Reference: Andrej Schmidt et al. J Am CollCardiolIntv. 2016;9(7):715-724.   The superiority of drug coated balloons compared to conventional balloons in femoropopliteal lesions have been shown by randomized studies, but only in short and simple lesions. The efficacy of drug coated balloons